US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Corgi NVO 2x Daily ETF

19.56

-0.4542-2.27%

Post-market: 20.010.4542+2.32%16:10 EDT

Volume:11

Turnover:219

Market Cap:293.41K

PE:- -

High:19.56

Open:20.01

Low:19.56

Close:20.01

52wk High:27.19

52wk Low:19.56

Shares:15.00K

Float Shares:15.00K

Volume Ratio:0.33

T/O Rate:0.07%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Novo Nordisk’s CagriSema Trial Targets Painful Diabetic Nerve Damage

Novo Nordisk's Semaglutide Injection Gets Chinese Approval for MASH Treatment

MT Newswires Live

Novo Nordisk Advances Oral Semaglutide Trial in Obesity: What Investors Should Watch

Novo Nordisk A/S Series B Stock Falls Wednesday

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/NVOC"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NVOC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOC\",,,,,undefined,":{"symbol":"NVOC","market":"US","secType":"STK","nameCN":"Corgi NVO 2x Daily ETF","latestPrice":19.5606,"timestamp":1789070400000,"preClose":20.0148,"halted":0,"volume":11,"hourTrading":{"tag":"盘后","latestPrice":20.0148,"preClose":19.5606,"latestTime":"16:10 EDT","volume":4,"amount":78.2424,"timestamp":1789071007782,"change":0.4542,"changeRate":0.02322,"amplitude":0},"delay":0,"changeRate":-0.022693207026800173,"floatShares":15000,"shares":15000,"eps":0,"marketStatus":"Not Yet Opened","change":-0.4542,"latestTime":"09-10 16:00:00 EDT","open":20.0148,"high":19.5606,"low":19.5606,"amount":219,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789113600000},"marketStatusCode":0,"adr":0,"listingDate":1784001600000,"exchange":"CBOE","adjPreClose":20.0148,"nav":20.01,"aum":300150,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":20.0148,"preClose":19.5606,"latestTime":"16:10 EDT","volume":4,"amount":78.2424,"timestamp":1789071007782,"change":0.4542,"changeRate":0.02322,"amplitude":0},"volumeRatio":0.325443},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOC\",,,,,undefined,":{"symbol":"NVOC","floatShares":15000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.325443,"shares":15000,"dividePrice":0,"high":19.5606,"amplitude":0,"preClose":20.0148,"low":19.5606,"week52Low":19.5606,"pbRate":"--","week52High":27.1863,"institutionHeld":0,"latestPrice":19.5606,"eps":0,"divideRate":0,"volume":11,"delay":0,"ttmEps":0,"open":20.0148,"prevYearClose":24.92,"prevWeekClose":21.8898,"prevMonthClose":20.8451,"prevQuarterClose":24.92,"fiveDayClose":22.1496,"twentyDayClose":21.6981},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVOC\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVOC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVOC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVOC\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666597368","title":"Novo Nordisk’s CagriSema Trial Targets Painful Diabetic Nerve Damage","url":"https://stock-news.laohu8.com/highlight/detail?id=2666597368","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666597368?lang=en_us&edition=fundamental","pubTime":"2026-09-11 00:30","pubTimestamp":1789057833,"startTime":"0","endTime":"0","summary":"Novo Nordisk ($NVO) announced an update on their ongoing clinical study. The study, officially titled “Efficacy and Safety of co Administered Cagri...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novo-nordisks-cagrisema-trial-targets-painful-diabetic-nerve-damage?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novo-nordisks-cagrisema-trial-targets-painful-diabetic-nerve-damage?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["THNR","OZEM","BK4585","LU0154236417.USD","NVOC","BK4532","PPH","LU1093756325.SGD","NVO","LU1093756168.USD","NVOH","IE00BKVL7J92.USD","BK4007","NVOX","IE00BZ1G4Q59.USD","BK4588","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666453561","title":"Novo Nordisk's Semaglutide Injection Gets Chinese Approval for MASH Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2666453561","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666453561?lang=en_us&edition=fundamental","pubTime":"2026-09-10 17:35","pubTimestamp":1789032909,"startTime":"0","endTime":"0","summary":"Novo Nordisk  said Thursday that China's National Medical Products Administration has approved its Semaglutide injection to treat metabolic-associated steatohepatitis, according to a Google translation of its Chinese statement.The company said that approval was based on results from its ESSENCE trial, which showed that 63% of patients treated with Semaglutide achieved MASH remission and no worsening of liver fibrosis, compared to 34% in the placebo group.Novo also said that 37% of patients treated with semaglutide demonstrated improvements in liver fibrosis and no worsening of MASH, compared to 22% in the placebo group.Treatment with the Smegglutide injection relieved liver inflammation in some patients and improved the \"scar\" tissue formed after long-term liver damage, the company added.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1093756168.USD","BK4007","BK4588","OZEM","PPH","IE00BKVL7J92.USD","NVO","THNR","NVOH","NVOX","LU0154236417.USD","IE00BZ1G4Q59.USD","NVOC","BK4599","BK4532","BK4585","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666534630","title":"Novo Nordisk Advances Oral Semaglutide Trial in Obesity: What Investors Should Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2666534630","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666534630?lang=en_us&edition=fundamental","pubTime":"2026-09-10 00:31","pubTimestamp":1788971502,"startTime":"0","endTime":"0","summary":"Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Novo Nordisk’s new Phase 3 trial, “Efficacy and Safety of Once Daily Oral ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-advances-oral-semaglutide-trial-in-obesity-what-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-advances-oral-semaglutide-trial-in-obesity-what-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4599","NVOX","BK4588","NVOC","IE00BKVL7J92.USD","LU0154236417.USD","NVOH","OZEM","LU1093756325.SGD","IE00BZ1G4Q59.USD","LU1093756168.USD","PPH","THNR","BK4585","BK4007","BK4532","NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666294531","title":"Novo Nordisk A/S Series B Stock Falls Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2666294531","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666294531?lang=en_us&edition=fundamental","pubTime":"2026-09-10 00:02","pubTimestamp":1788969720,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novo Nordisk A/S Series B dropped 1.1% to DKK288.90 Wednesday on what proved to be an overall unfavorable trading session for the stock market, with the OMX Nordic 40 Index falling 1.1% to 2,686.31.This was the stock's second consecutive day of losses.The company closed DKK121.05 short of its 52-week high of DKK409.95, which the company reached on January 23, 2026.Trading volume was 4,429,973, compared to the 50-day average trading volume of 4,078,075.Data source: Dow Jones Market Data, FactSet","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","PPH","IE00BZ1G4Q59.USD","LU1093756168.USD","LU1093756325.SGD","OZEM","BK4532","IE00BKVL7J92.USD","LU0154236417.USD","THNR","NVO","BK4007","NVOX","NVOH","NVOC","BK4599","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":18,"pageCount":1,"totalSize":72,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NVOC\",params:#limit:6,delay:false,,,undefined,":[]}}